Related references
Note: Only part of the references are listed.Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice
Kai Zhou et al.
ACTA PHARMACOLOGICA SINICA (2019)
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer
Stephen J. Bagley et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma
Yuan Li et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel
Haifeng Qiu et al.
CELL CYCLE (2018)
The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model
Jiuhuan Feng et al.
ONCOTARGETS AND THERAPY (2018)
Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
Xiangheng Chen et al.
JOURNAL OF CANCER (2018)
Anti-Angiogenics: Their Value in Lung Cancer Therapy
Melanie Janning et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
Muhammad Khan et al.
MEDICINE (2018)
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
Min Wu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer
Zhi-Gang Bai et al.
ONCOTARGETS AND THERAPY (2018)
The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
Meng-Dan Xu et al.
ONCOGENESIS (2018)
Bevacizumab in advanced lung cancer: state of the art
Sandra Assoun et al.
FUTURE ONCOLOGY (2017)
Angiogenesis Inhibitors in NSCLC
Anna Manzo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
Qiu-Xia Peng et al.
ONCOTARGET (2017)
Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer
Yi Lin et al.
ONCOTARGET (2017)
Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy
Annette Orleth et al.
JOURNAL OF DRUG TARGETING (2016)
Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
Chaolun An et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters
Xiao Bao et al.
THERANOSTICS (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Apatinib for molecular targeted therapy in tumor
Haijun Zhang
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Masabumi Shibuya
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS
A. J. Scott et al.
DRUGS OF TODAY (2015)
Tumor Texture Analysis in 18F-FDG PET: Relationships Between Texture Parameters, Histogram Indices, Standardized Uptake Values, Metabolic Volumes, and Total Lesion Glycolysis
Fanny Orlhac et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Mark A. Socinski et al.
CHEST (2013)
Stratification of 18F-Labeled PET Imaging Agents for the Assessment of Antiangiogenic Therapy Responses in Tumors
Julian L. Goggi et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Understanding and targeting resistance to anti-angiogenic therapies
Jeffrey M. Clarke et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2013)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Tumor-derived vascular endothelial growth factor (VEGF)-A facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway
Wenbo Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
The Antitumor Activity of NK012, an SN-38-Incorporating Micelle, in Combination With Bevacizumab Against Lung Cancer Xenografts
Hirotsugu Kenmotsu et al.
CANCER (2010)
Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
Nikolaus Schicher et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The lessons of GIST - PET and PET/CT: A new paradigm for imaging
Annick D. Van den Abbeele
ONCOLOGIST (2008)
Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning
Wolfgang A. Weber et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft
Satoshi Inoue et al.
MOLECULAR THERAPY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
RK Jain et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis
AP Meert et al.
BRITISH JOURNAL OF CANCER (2002)
Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
RS Kerbel et al.
CANCER AND METASTASIS REVIEWS (2001)
Share Paper
